Lab
Specialty Laboratories INC
Specialty Laboratories INC was paid $16.76M by Medicaid between Jan 2018 and Dec 2024, across 179 billing codes. Its largest line is 87799, — 29% of everything it billed.
33Billing provider infoSPECIALTY LABORATORIES INC
WEST HILLS, CA 91304
WEST HILLS, CA 91304
33aNPI1811997711assigned 07/21/2005
33bProvider typeClinical Medical Laboratory
28Total paid$16.76M
24GClaims524,721
24DCodes billed179
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#54 of 561
Median peer was paid$222K
This provider vs. median76×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 173,967 | $6.31M | |
| 2019 | 143,294 | $5.76M | |
| 2020 | 46,510 | $1.02M | |
| 2021 | 46,288 | $1.05M | |
| 2022 | 41,165 | $946K | |
| 2023 | 55,364 | $1.22M | |
| 2024incomplete | 18,133 | $446K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87799 | 29% | 67,734 | 26,147 | $4.87M | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.5% | 28,631 | 24,520 | $1.26M |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 7.1% | 31,493 | 25,455 | $1.20M |
| 87512 | 6.9% | 31,769 | 25,594 | $1.16M | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6.9% | 31,327 | 24,456 | $1.16M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.6% | 30,252 | 24,477 | $1.11M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 6.1% | 16,280 | 14,296 | $1.01M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 6.0% | 35,334 | 29,146 | $1.01M |
| 84403 | 4.5% | 34,617 | 33,284 | $752K | |
| 82652 | 3.6% | 20,398 | 19,901 | $604K | |
| 84402 | 2.3% | 19,013 | 18,398 | $381K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 4,393 | 4,334 | $326K |
167 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 11,884 | $205K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 1.0% | 1,038 | $176K |
| 84270 | <1% | 7,623 | $126K | |
| 84425 | <1% | 8,705 | $124K | |
| 86003 | <1% | 4,170 | $75K | |
| 86235 | <1% | 1,646 | $74K | |
| 84207 | <1% | 4,039 | $71K | |
| 80177 | <1% | 6,720 | $63K | |
| 83520 | <1% | 7,743 | $63K | |
| 84182 | <1% | 888 | $59K | |
| 80180 | <1% | 1,936 | $54K | |
| 81329 | <1% | 538 | $53K | |
| 80175 | <1% | 4,400 | $46K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 607 | $45K |
| 80299 | <1% | 3,668 | $40K | |
| 80159 | <1% | 3,972 | $38K | |
| 84252 | <1% | 3,900 | $37K | |
| 83655 | <1% | 3,865 | $34K | |
| 84630 | <1% | 5,611 | $33K | |
| 82525 | <1% | 2,867 | $25K | |
| 82365 | <1% | 2,857 | $20K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 228 | $20K |
| 82507 | <1% | 1,246 | $20K | |
| 84255 | <1% | 1,383 | $19K | |
| 84238 | <1% | 630 | $18K | |
| 82397 | <1% | 2,956 | $17K | |
| 82180 | <1% | 3,302 | $16K | |
| 84590 | <1% | 1,905 | $15K | |
| 80235 | <1% | 1,525 | $13K | |
| 80203 | <1% | 1,614 | $13K | |
| 84446 | <1% | 1,242 | $12K | |
| 83735 | <1% | 2,733 | $12K | |
| 86215 | <1% | 2,049 | $12K | |
| 82175 | <1% | 1,044 | $11K | |
| 82040 | <1% | 2,417 | $11K | |
| 86008 | <1% | 1,097 | $11K | |
| 84591 | <1% | 2,028 | $10K | |
| 83825 | <1% | 1,079 | $10K | |
| 83945 | <1% | 1,267 | $10K | |
| 80050 | General health panel | <1% | 765 | $9K |
| 82607 | <1% | 1,573 | $8K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,786 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,992 | $7K |
| 82570 | <1% | 2,378 | $7K | |
| 83516 | <1% | 837 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,019 | $6K |
| 82140 | <1% | 630 | $5K | |
| 83018 | <1% | 349 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 290 | $5K |
| 82746 | <1% | 1,116 | $5K | |
| 82340 | <1% | 1,250 | $5K | |
| 84300 | <1% | 1,459 | $5K | |
| 86682 | <1% | 457 | $5K | |
| 86762 | <1% | 356 | $5K | |
| 80061 | Lipid panel | <1% | 1,258 | $4K |
| 87340 | <1% | 526 | $4K | |
| 86803 | <1% | 457 | $4K | |
| 86617 | <1% | 175 | $4K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,729 | $4K |
| 84105 | <1% | 1,271 | $4K | |
| 84392 | <1% | 1,183 | $4K | |
| 84560 | <1% | 1,310 | $4K | |
| 86480 | <1% | 75 | $4K | |
| 84133 | <1% | 1,276 | $4K | |
| 86618 | <1% | 269 | $4K | |
| 82670 | <1% | 511 | $3K | |
| 86592 | <1% | 1,052 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,110 | $3K |
| 86038 | <1% | 476 | $3K | |
| 80201 | <1% | 300 | $3K | |
| 82300 | <1% | 290 | $3K | |
| 86665 | <1% | 109 | $3K | |
| 82728 | <1% | 893 | $3K | |
| 83986 | <1% | 1,241 | $3K | |
| 84597 | <1% | 345 | $3K | |
| 86001 | <1% | 961 | $3K | |
| 86255 | <1% | 260 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 74 | $2K |
| 83001 | <1% | 334 | $2K | |
| 80362 | <1% | 2,927 | $2K | |
| 83785 | <1% | 159 | $2K | |
| 86060 | <1% | 486 | $2K | |
| 84439 | <1% | 598 | $2K | |
| 82657 | <1% | 144 | $2K | |
| 87046 | <1% | 282 | $1K | |
| 86317 | <1% | 104 | $1K | |
| 83540 | <1% | 644 | $1K | |
| 83002 | <1% | 260 | $1K | |
| 87481 | <1% | 27 | $1K | |
| 84481 | <1% | 316 | $1K | |
| 84146 | <1% | 239 | $1K | |
| 84144 | <1% | 237 | $1K | |
| 82495 | <1% | 121 | $1K | |
| 83550 | <1% | 459 | $1K | |
| 82390 | <1% | 211 | $990.93 | |
| 86160 | <1% | 65 | $914.62 | |
| 87209 | <1% | 87 | $912.13 | |
| 87517 | <1% | 25 | $875.37 | |
| 86644 | <1% | 78 | $856.27 | |
| 86140 | <1% | 271 | $697.75 | |
| 80197 | <1% | 103 | $671.83 | |
| 82166 | <1% | 70 | $628.37 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 28 | $622.00 |
| 86696 | <1% | 30 | $621.20 | |
| 83970 | <1% | 24 | $560.23 | |
| 85027 | <1% | 272 | $545.86 | |
| 86695 | <1% | 30 | $473.04 | |
| 87177 | <1% | 83 | $442.18 | |
| 85652 | <1% | 312 | $431.97 | |
| 80361 | <1% | 445 | $424.96 | |
| 86645 | <1% | 66 | $415.71 | |
| 86376 | <1% | 41 | $395.04 | |
| 84480 | <1% | 59 | $370.03 | |
| 82784 | <1% | 52 | $355.36 | |
| 86431 | <1% | 104 | $342.81 | |
| 82785 | <1% | 26 | $296.66 | |
| 84153 | <1% | 32 | $295.68 | |
| 83525 | <1% | 64 | $291.85 | |
| 82542 | <1% | 17 | $289.05 | |
| 80365 | <1% | 421 | $262.18 | |
| 86200 | <1% | 35 | $250.05 | |
| 86039 | <1% | 40 | $228.67 | |
| 83615 | <1% | 71 | $224.96 | |
| 86704 | <1% | 34 | $214.50 | |
| 86361 | <1% | 14 | $205.39 | |
| 82105 | <1% | 18 | $204.30 | |
| 80356 | <1% | 333 | $201.18 | |
| 86780 | <1% | 12 | $175.27 | |
| 80165 | <1% | 12 | $157.18 | |
| 83874 | <1% | 14 | $152.25 | |
| 86787 | <1% | 17 | $141.32 | |
| 86706 | <1% | 28 | $140.42 | |
| 84436 | <1% | 39 | $131.66 | |
| 84550 | <1% | 51 | $128.56 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 34 | $115.13 |
| 81001 | <1% | 101 | $105.36 | |
| 86225 | <1% | 12 | $100.82 | |
| 86777 | <1% | 13 | $99.96 | |
| 82310 | <1% | 67 | $98.72 | |
| 80323 | <1% | 18 | $88.58 | |
| 82043 | <1% | 82 | $79.98 | |
| 80348 | <1% | 365 | $78.78 | |
| 83090 | <1% | 15 | $61.92 | |
| 84156 | <1% | 34 | $60.57 | |
| 84100 | <1% | 16 | $45.08 | |
| 86708 | <1% | 12 | $43.35 | |
| 85610 | <1% | 28 | $36.12 | |
| 82947 | <1% | 14 | $28.05 | |
| 82523 | <1% | 75 | $24.03 | |
| 80349 | <1% | 31 | $13.02 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13 | $11.30 |
| 83921 | <1% | 18 | $2.07 | |
| 80332 | 0% | 49 | $0.00 | |
| 80369 | 0% | 325 | $0.00 | |
| 80355 | 0% | 334 | $0.00 | |
| 80346 | 0% | 348 | $0.00 | |
| 80366 | 0% | 334 | $0.00 | |
| 80354 | 0% | 323 | $0.00 | |
| 83992 | 0% | 317 | $0.00 | |
| 80373 | 0% | 344 | $0.00 | |
| 80360 | 0% | 318 | $0.00 | |
| 80372 | 0% | 316 | $0.00 | |
| 80358 | 0% | 321 | $0.00 | |
| 80324 | 0% | 336 | $0.00 | |
| 80374 | 0% | 320 | $0.00 | |
| 80368 | 0% | 320 | $0.00 | |
| 80353 | 0% | 326 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.